ZT002

– ZT002 was safe and well tolerated in both biweekly and monthly dosing arms in patients with overweight or obesity with a tolerability profile aligned with the GLP-1RA class – The open-label extension with ZT002 120 mg, once-monthly, showed 17.1% reduction in body weight at 30 weeks BEIJING, Sept. 12, 2024 /PRNewswire/ -- Beijing QL Biopharmaceutical Co., Ltd. ("QL Biopharm" or the "Company"), a clinical stage biopharmaceutical company developing innovative biologic drugs for the treatment of metabolic diseases, today announces Phase 1c clinical data for its lead drug candidate ZT002 was presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024, Madrid, Spain. The presentation titled 'ZT002, a novel ultra long-acting GLP-1 receptor agonist in adults with overweight or obesity: A randomized, placebo-controlled, multiple ascending dose phase 1c study' highlighted recent findings on QL Biopharm's lead drug candidate ZT002 - a novel ultra long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) in development for obesity with monthly subcutaneous administration. The study enrolled 28 overweight/obese patients in Part A in two cohorts. Eligible participants were randomly assigned to receive biweekly (Q2W) subcutaneous injections of ZT002 (dose escalated to 40 or 80 mg; n=10+10) or matched placebo (n=4+4) for a 12- or 14- week treatment period, in the 40 mg and 80 mg dose arms, respectively. The primary endpoints were safety and tolerability, and secondary endpoints were pharmacokinetics, pharmacodynamics, and immunogenicity. All endpoints were met. Following a 6-week off-drug period, for assessment of pharmacokinetics, Part A was followed by an open-label extension (Part B). In this extension patients from the ZT002 80 mg Q2W cohort voluntarily participated in an additional 12 weeks of treatment with a once-monthly (Q4W) administration of ZT002 120 mg (n=8). The primary endpoints were safety and tolerability, and secondary endpoints were pharmacokinetics, pharmacodynamics, and immunogenicity. All endpoints were met. Key conclusions from today's presentation are outlined below: ZT002 was considered safe and well tolerated across the investigated dose range, with a favorable tolerability profile aligned with the GLP-1RA class. The tolerability with both Q2W and Q4W dosing improved over time. The majority of adverse events (AEs) were mild or moderate in severity, no serious AEs were reported in the ZT002 treatment groups. Gastrointestinal (GI) treatment emergent adverse events were consistent with the GLP-1RA class; Most common treatment-related adverse events were nausea, vomiting, and diarrhea, occurring primarily during dose escalation and decreasing once target dose was reached. The GI AE profile of monthly dosing in Part B appeared similar to biweekly dosing in Part A In Part A, ZT002 demonstrated statistically significantly higher weight reduction compared to placebo with 13.0% body weight reduction from baseline to 14 weeks with ZT002 80 mg Q2W (p<0.001 vs placebo 1.7% body weight reduction). 9.6% body weight reduction from baseline to 12 weeks with ZT002 40 mg Q2W (p<0.001 vs placebo 0.8% body weight reduction). In Part B, a 17.1% body weight reduction from baseline was seen at 30 weeks, when further administering ZT002 120 mg once-monthly (after a 6-week off-drug period). All doses of ZT002 showed improved cardiometabolic parameters including blood pressure, waist circumference, insulin sensitivity, lipids, and liver enzyme levels. The results support further clinical investigation of ZT002 dosed monthly as a treatment for obesity. A Phase 2 program evaluating ZT002 for chronic weight management has been initiated in China and regulatory interaction is planned with U.S. FDA to advance the program outside China. Dr. Zhang Xujia, Ph.D., Founder, Chairman and Chief Executive Officer of QL Biopharm said: "We are pleased to present data highlighting the potential of ZT002 and its promising clinical profile in obesity care. The additional advantage of monthly dosing simplifies life for patients living with obesity. We look forward to advancing the Phase 2 program for ZT002 in overweight and obesity and providing further updates in due course." Abstracts are available on the EASD website here, and on the QL Biopharm website here. NOTES TO EDITORS About QL Biopharm QL Biopharm is a clinical-stage biopharmaceutical company focused on developing novel best-in-class peptide therapeutics for metabolic diseases. The Company leverages its proprietary E. coli manufacturing process enabling rapid and cost-effective scaling of manufacturing for high volume markets. The lead drug candidate, ZT002, is an ultra long-acting subcutaneously administered GLP-1 receptor agonist, currently in a Phase 2 study for obesity and in Phase 1 for type 2 diabetes. In Phase 1 studies, ZT002 demonstrated potential for once-monthly dosing with compelling weight loss and tolerability consistent with the GLP-1RA class. The Company is also advancing a broader portfolio of novel preclinical assets for the treatment of metabolic diseases, in addition to its biosimilar semaglutide program, currently in Phase 3. QL Biopharm is led by a team of pharma industry veterans with expertise in E. coli–based peptide manufacturing and the development of drugs for metabolic diseases. The Company is backed by leading professional life science investors. For additional information, please visit About EASD The European Association for the Study of Diabetes e.V. (EASD) is a membership-based academic non-profit organization. It was founded in 1965 and its headquarters is based in Duesseldorf, Germany. The aims of the Association are to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application. SOURCE Beijing QL Biopharmaceutical Co., Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

01 行业新闻 丨首部医疗器械管理法草案征求意见 8月28日，中国国家药品监督管理局（NMPA）官网发布《中华人民共和国医疗器械管理法（草案征求意见稿）》（以下简称《草案》），对外公开征求意见。《草案》强调，医疗器械管理应当以人民健康为中心，树立安全发展理念，遵循风险管理、全程管控、科学监管、社会共治的原则，保障医疗器械的安全、有效、可及。 此次发布的《草案》共十一章，一百九十条，包括总则、医疗器械标准和分类、医疗器械研制、医疗器械生产、医疗器械经营、医疗器械进出口、医疗器械使用、医疗器械警戒与召回、监督管理、法律责任和附则，覆盖医疗器械全生命周期质量安全监管。 《草案》还采取列举式规定，特别明确境内责任人与注册人、备案人共同承担上市后风险管控、不良事件监测报告、召回等义务，协助注册人、备案人履行上市后研究、建立质量管理体系等义务，以进一步加强境内责任人责任。（NMPA） 02 企业动态 丨海创药业1类NASH创新药获批临床 8月26日，中国国家药监局药品审评中心（CDE）官网最新公示，海创药业申报的1类新药HP515片获批临床试验默示许可，拟开发治疗非酒精性脂肪性肝炎（NASH）。根据海创药业公开资料，这是一款小分子甲状腺激素β受体（THR-β）激动剂。本次为该产品首次在中国获批IND。HP515片正是一款小分子THR-β激动剂，能选择性地激活肝脏THRβ。肝脏中的THRβ在维持血液中的胆固醇和甘油三酯的代谢平衡中发挥重要作用，同时能抑制脂肪在肝脏中的异常堆积，促进肝细胞中线粒体的生成，提高脂肪在肝细胞中的代谢。（海创药业） 丨质肽生物GLP-1新药申报临床 8月27日，CDE官网最新公示，北京质肽生物医药科技有限公司申报的1类新药ZT006片的6项临床申请获得受理。公开资料显示，ZT006 是一款新一代口服GLP-1药物，拟开发治疗糖尿病和肥胖症等。该公司管线中有多款在研重组蛋白创新药和生物类似药。除了其司美格鲁肽注射液生物类似药ZT001，质肽生物的ZT002注射液也正在临床开发阶段。ZT002是一种新型超长效GLP-1R激动剂。（质肽生物） 丨百济神州BTK靶向降解剂癌症新药获FDA快速通道资格 8月27日，百济神州宣布，美国FDA授予BGB-16673快速通道资格，用于治疗既往接受过至少两线治疗（包括BTK抑制剂和BCL2抑制剂）的复发/难治性（R/R）慢性淋巴细胞白血病或小淋巴细胞淋巴瘤（CLL/SLL）成年患者。BGB-16673是一种口服、靶向BTK的在研嵌合式降解激活化合物（CDAC）。BGB-16673是一种口服靶向布鲁顿氏酪氨酸激酶（BTK）的嵌合式降解激活化合物（CDAC），是百济神州CDAC平台首款在研药物。（百济神州） 丨智翔金泰IL-17A单抗获批上市 8月27日，智翔金泰宣布，NMPA已批准该公司1类新药赛立奇单抗注射液上市，用于中、重度斑块状银屑病的治疗。根据智翔金泰发布新闻稿，赛立奇单抗是一款抗IL-17A单克隆抗体注射液。赛立奇单抗（xeligekimab，GR1501）是由智翔金泰研发的一款重组全人源抗IL-17A单克隆抗体。IL-17A是一种天然存在的细胞因子，参与正常的炎症和免疫反应，它在斑块状银屑病、银屑病关节炎和强直性脊柱炎的发病机理中起关键作用。（智翔金泰） 丨传奇生物CAR-T在国内获批 8月27日，NMPA显示，传奇生物的西达基奥仑赛已获批准上市，用于治疗既往接受过一种蛋白酶抑制剂和一种免疫调节剂治疗后复发或难治性多发性骨髓瘤。这是国内获批的第六款CAR-T，其他5款CAR-T产品价格基本都在百万元级别。西达基奥仑赛是一款靶向BCMA的CAR-T产品，此前已经在美国上市销售，是中国首个获FDA批准的细胞治疗产品。上市以来，西达基奥仑赛的销售额近乎翻倍增长，2023年全年销售额约5亿美元，同期增长273%。（健识局） 丨石药集团ADC创新药联合疗法获批临床 8月27日，CDE官网最新公示，石药集团两款1类新药SYS6010与重组抗PD-1全人源单克隆抗体注射液联合疗法获批临床，拟开发用于治疗EGFR及ALK野生型晚期非小细胞肺癌和其他晚期实体瘤。SYS6010（又称CPO301）是石药集团开发的一款靶向EGFR的ADC，拟用于治疗复发/难治性或EGFR靶向治疗（如第三代EGFR抑制剂）无效的转移性EGFR突变非小细胞肺癌患者。临床前毒理学和安全药理学研究显示该产品具有良好的安全性和耐受性。（CDE、石药集团） 丨优时比重症肌无力新药在中国申报上市 8月28日，CDE官网最新公示，优时比（UCB）公司申报的泽勒普肽注射液上市申请获得受理。Zilucoplan是一款新型大环肽类C5补体抑制剂。该产品通过抑制末端补体途径激活和膜攻击复合物（MAC）下游组装的双重作用机制，进而防止它们破坏离子通道传导和神经肌肉信号传递。Zilucoplan已经于2023年10月获美国FDA批准治疗抗乙酰胆碱受体（AChR）抗体阳性的全身型重症肌无力（gMG）成年患者。（CDE、优时比） 丨赛诺菲糖尿病新药替利珠单抗在中国申报上市 8月28日，CDE官网公示，赛诺菲（Sanofi）申报的替利珠单抗注射液的上市申请获得受理。就在上周，该药物被CDE纳入优先审评，用于成人和8岁及以上儿童1型糖尿病2期患者，以延缓3期1型糖尿病发病。公开资料显示，替利珠单抗（teplizumab）是一款CD3单抗药物，是用于延缓1型糖尿病发病的创新靶向疗法。替利珠单抗是一种“first-in-class”CD3靶向单克隆抗体，它能从病因上实现对胰岛β细胞的保护，进而延缓1型糖尿病发病近3年。（CDE、赛诺菲） 丨阿斯利康BTK抑制剂阿可替尼新适应症在中国申报上市 8月28日，CDE官网最新公示，阿斯利康申报的acalabrutinib Maleate片上市申请已获得受理。公开资料显示，acalabrutinib（通用名：阿可替尼胶囊）是一款布鲁顿氏酪氨酸激酶（BTK）抑制剂，此前已经在中国获批两项适应症。根据阿斯利康官网管线信息，推测此次阿可替尼申报上市的新适应症可能是一线治疗慢性淋巴细胞白血病（CLL）。（CDE、阿斯利康） 丨信达生物披露2024年上半年研发管线主要进展 8月28日，信达生物披露了2024年中期业绩和公司进展，同时披露了关键后期管线进展以及早期管线储备。根据信达生物新闻稿，该公司商业化产品目前增至11款。其中以达伯舒®为代表的肿瘤产品线今年预计增至10款产品，下半年将再新添1款肺癌靶向药物他雷替尼（ROS1抑制剂）；综合产品线心血管及代谢（CVM）领域递交3项新药上市申请（NDA），包括玛仕度肽（GLP-1R/GCGR）治疗肥胖和糖尿病，以及替妥尤单抗（IGF-1R）治疗甲状腺眼病。目前，信达生物已有7个新产品在NDA或关键注册临床阶段，18个产品进入临床研究阶段。以下摘录信达生物主要产品管线信息。（信达生物） 丨通化金马药业阿尔茨海默病1类新药申报上市 8月29日，CDE官网最新公示，通化金马药业申报的琥珀八氢氨吖啶片1类新药上市申请获得受理。这是通化金马开发的一款小分子乙酰胆碱酯酶抑制剂，可以同时抑制乙酰胆碱酯酶和丁酰胆碱酯酶，主要开发用于治疗轻中度阿尔茨海默病。2023年9月，通化金马宣布琥珀八氢氨吖啶片治疗轻中度阿尔茨海默病的3期研究完成。结果显示，琥珀八氢氨吖啶片对阿尔茨海默病评定量表认知部分（ADAS-cog）的改善效果具有显著的临床意义。安全性方面，琥珀八氢氨吖啶片组不良事件的发生率低于对照组。与安慰剂组比较，其结果具有统计学意义。(通化金马） 丨复诺健生物溶瘤病毒1类新药拟纳入突破性治疗品种 8月29日，CDE官网最新公示，由中生复诺健生物申报的重组人IL12/15-PDL1B单纯疱疹I型溶瘤病毒注射液（Vero细胞）拟纳入突破性治疗品种，适应症为：经标准治疗失败的晚期肝细胞癌（HCC）。公开资料显示，这应该是复诺健生物（Virogin Biotech）研发的新型抗肿瘤免疫增强型I型单纯疱疹溶瘤病毒在研产品VG161。今年4月披露的一项临床数据显示，既往接受过包括检查点抑制剂在内的二线治疗失败的肝细胞癌患者接受VG161单药治疗，获得了显著的临床获益。(复诺健生物) 丨三生制药重组人血小板生成素新适应症申报上市 8月30日，CDE官网最新公示，三生制药申报的重组人血小板生成素注射液新适应症上市申请获得受理。今年7月底，三生制药宣布，重组人血小板生成素注射液治疗拟择期行侵入性手术的慢性肝病相关血小板减少症患者的3期临床研究达到预设主要终点，三生制药计划于近期向NMPA递交新增适应症上市申请。因此，推测本次申报上市的适应症为拟择期行侵入性手术的慢性肝病相关血小板减少症患者。（三生制药） *声明：本文不构成任何投资建议，仅出于传递更多信息之目的。 ------------------------------ 「长按」二维码添加小达「进群」 与更多行业伙伴共探市场前沿资讯 艾美达医药咨询 艾美达（北京）医药信息咨询有限公司，成立于2014年4月，是一家专业的医药行业咨询服务提供商。公司致力于将产业政策研究与真实世界的数据挖掘深度结合，洞悉行业政策对市场的影响，通过专业的研究提供前瞻性的市场分析，为企业产品上市后的市场准入提供整体解决方案。